A-Meb135 mg

A-Meb is a direct-acting (musculotropic) antispasmodic used for gastrointestinal smooth-muscle spasm. Its main uses, classified by strength of evidence, are:

Established / Guideline-Supported Uses

• Irritable Bowel Syndrome (IBS): Symptomatic relief of abdominal pain, cramping, and altered bowel habit associated with IBS, once the diagnosis has been confirmed by a physician.
• Gastrointestinal smooth-muscle spasm secondary to organic disease (e.g. diverticular disease), for relief of associated colicky pain.

Adjunct / Procedural Use

• Occasionally used before certain diagnostic procedures (e.g. barium enema) to reduce colonic spasm and improve visualization, at the discretion of the treating physician.

A-Meb is intended for symptomatic relief only after an underlying diagnosis has been established; it is not intended for undiagnosed acute abdominal pain.

Each tablet/capsule contains Mebeverine Hydrochloride as the active ingredient, commonly available as:

• Immediate-release tablets containing Mebeverine Hydrochloride 135 mg
• Sustained/modified-release capsules containing Mebeverine Hydrochloride 200 mg

Excipients vary by manufacturer and formulation; refer to the specific product package insert for the complete excipient list.

A-Meb is a musculotropic (direct-acting) antispasmodic agent widely used for the symptomatic management of gastrointestinal smooth-muscle spasm, most commonly in irritable bowel syndrome (IBS). Chemically, it is related to papaverine.

Unlike older antispasmodics such as hyoscine (an antimuscarinic/anticholinergic agent), A-Meb acts directly on gastrointestinal smooth muscle rather than through blockade of muscarinic (acetylcholine) receptors. This gives it a more GI-selective mechanism and, in clinical use, a lower incidence of classic anticholinergic effects such as dry mouth, blurred vision, urinary retention, and tachycardia, although these effects are not entirely absent in every patient. A-Meb is available in Bangladesh as an oral tablet/capsule and is a commonly prescribed antispasmodic for IBS-related symptoms.

Gastrointestinal antispasmodic (musculotropic, direct-acting smooth-muscle relaxant)

Mebeverine Hydrochloride exerts a direct (musculotropic) relaxant action on gastrointestinal smooth muscle. Proposed mechanisms include a local anesthetic-like reduction of sodium influx into smooth-muscle cells and modulation of calcium reuptake/efflux, which reduces excessive muscle contraction (spasm) without producing sustained atony of the gut wall.

A key pharmacological distinction from classic antimuscarinic antispasmodics (e.g. hyoscine/atropine-type agents) is that Mebeverine Hydrochloride does not act primarily by blocking muscarinic acetylcholine receptors. As a result, it does not significantly suppress normal gastrointestinal motility and is associated with a lower burden of systemic anticholinergic side effects, though it is not entirely free of them in all patients.

Mebeverine Hydrochloride is largely metabolized (chiefly by esterase hydrolysis) with metabolites eliminated mainly via the kidneys.

A-Meb tablets/capsules should be swallowed whole with water approximately 20 minutes before meals. Do not crush or chew sustained-release capsules. Take only as directed by the prescribing physician.

No major, well-established clinically significant drug interactions have been documented for A-Meb, which is consistent with its lack of significant systemic antimuscarinic (anticholinergic) activity compared with older antispasmodics. However, formal interaction studies are limited.

As a general precaution, inform your physician or pharmacist about all prescription medicines, over-the-counter drugs, and herbal/supplement products you are taking before starting A-Meb, so that any theoretical or newly identified interaction can be assessed.

A-Meb is generally well tolerated. Reported adverse effects include:

• Common: Dizziness, headache, nausea, epigastric discomfort, constipation, or diarrhoea.
• Uncommon/Rare: Hypersensitivity reactions such as skin rash, itching, urticaria, and, rarely, angioedema or other allergic reactions.

Because A-Meb has minimal systemic anticholinergic activity, classic antimuscarinic effects (dry mouth, blurred vision, urinary retention) are less frequent than with older antispasmodics such as hyoscine, though isolated reports exist and cannot be entirely excluded.

Seek medical attention promptly for any signs of a serious allergic reaction (e.g. facial/throat swelling, difficulty breathing, widespread rash).

Pregnancy: Data on the use of A-Meb in pregnant women are limited. As a precaution, A-Meb should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: A-Meb passes into breast milk in small amounts. Because data on infant safety are limited, use during breastfeeding is not generally recommended unless a physician determines the benefit outweighs the potential risk; consult a physician before use while breastfeeding.

• A-Meb should be used only after a physician has established the underlying diagnosis; it is not intended for undiagnosed acute abdominal pain, as this may mask a condition requiring urgent evaluation.
• Porphyria: Data are limited; some references advise caution when using A-Meb in patients with known porphyria. Discuss with a physician if you have this condition.
• Use with caution in patients with significant hepatic or renal impairment, given limited specific data (see Use in Special Populations).
• See Contraindications for absolute contraindications (hypersensitivity, paralytic ileus) and Pregnancy and Lactation for use in pregnancy/breastfeeding.
• If symptoms do not improve, or if new or worsening abdominal symptoms occur, stop A-Meb and consult a physician promptly.

There is limited published experience with overdose of A-Meb; no specific antidote is known. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Management is generally supportive, guided by the treating medical team based on the patient's symptoms.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of A-Meb have not been well established in young children; standard adult formulations are generally not recommended below the age range specified in local product labeling. See Pediatric Uses for further detail.

Elderly

No specific dose adjustment is well established for elderly patients; A-Meb may be used with routine clinical caution, considering comorbidities and concomitant medications.

Renal/Hepatic Impairment

Data are limited; use A-Meb with caution and medical supervision in patients with significant renal or hepatic impairment.

Pregnancy and Breastfeeding

See Pregnancy and Lactation for detailed guidance.

A-Meb is generally used for as short a period as needed to control symptoms, often for a few days up to about two weeks per episode, and only while symptoms are present. If symptoms persist beyond this period, recur frequently, or worsen, a physician should reassess the diagnosis and treatment plan; long-term continuous use should only occur under ongoing medical supervision.

Antispasmodics, musculotropic (direct-acting gastrointestinal smooth-muscle relaxants)

Mebeverine Hydrochloride acts directly on gastrointestinal smooth muscle (a musculotropic mechanism) rather than by blocking muscarinic acetylcholine receptors as older antispasmodics (e.g. hyoscine) do. Proposed cellular actions include a local anesthetic-type reduction of sodium ion influx and modulation of calcium ion movement across the smooth-muscle cell membrane, which reduces excessive spasm/hypercontractility.

Because normal peristaltic tone is not significantly blocked, Mebeverine Hydrochloride relieves spasm without causing significant intestinal atony, and, since it does not primarily work via antimuscarinic blockade, it is associated with fewer classic anticholinergic side effects than atropine-like antispasmodics.

The safety and efficacy of A-Meb have not been well established in young children. Standard adult tablet/capsule formulations are generally not recommended for use below the age threshold specified in the local product labeling (commonly not advised in children under 10 years for standard formulations in several markets). Where a physician judges that treatment with A-Meb is appropriate in an older child, dosing must be individualized, supervised, and based on the specific product's approved labeling. Parents/caregivers should not give A-Meb to a child without a physician's specific instruction.